Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
Key Highlights
- ➤Artiva (ARTV) discontinued AlloNK development, including the planned Phase 3 pivotal trial
- ➤Longer-term data failed to meet the required clinical-response durability threshold
- ➤Artiva disclosed two Grade 5 events, including fatal leukoencephalopathy likely linked to fludarabine toxicity
- ➤Workforce reduction targets approximately 94% as Artiva evaluates strategic alternatives
- ➤Cash, cash equivalents and investments totaled approximately $319.1 million as of September 30, 2026
Expert Statements
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“After careful consideration, we have made the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives”
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority.”
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families.”
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“We plan to provide findings from the first case, which was assessed as likely related to fludarabine toxicity, given its widespread use in cell therapy conditioning regimens.”
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“I am incredibly proud of the Artiva team and grateful for their dedication, professionalism and deep commitment to patients.”
Fred Aslan, Chief Executive Officer of Artiva Biotherapeutics
“We also thank the patients, families and investigators who have contributed to advancing our understanding of AlloNK and its potential role in the treatment of autoimmune diseases.”
* Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial
* Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, updated longer-term data showed that durability of clinical response did not meet the threshold the Company required to support continued development
Get started
Create a free account to read the full story.